Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN) -- Ignore unavailable to you. Want to Upgrade?

To: dch who wrote (147)	8/23/1999 9:07:00 PM
From: Curtis E. Bemis	Read Replies (1) \| Respond to of 395

And this-- 2 SBIR Grants today-- marketwatch.newsalert.com Repligen Awarded Two SBIR Grants PR Newswire - August 23, 1999 14:52 National Cancer Institute and National Science Foundation to Support Research NEEDHAM, Mass., Aug. 23 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has been awarded Phase 1 SBIR grants from the National Cancer Institute (NCI) and the National Science Foundation (NSF) to support the discovery of novel active compounds from its combinatorial chemical libraries. The NCI grant will support the characterization of inhibitors of heparanase previously discovered by Repligen in a combinatorial library of organic compounds. Heparanase is implicated in several disease associated processes including angiogenesis, metastasis and inflammation. The NSF award will fund the synthesis of a combinatorial library of organic compounds which will be screened for their ability to selectively extract biopharmaceutical proteins from complex production media. "These grant awards are consistent with our strategy of obtaining third party funding for preclinical research projects in order to focus our proprietary investments on the clinical development of secretin for autism and CTLA4 for organ transplantation," stated Walter C. Herlihy, Ph.D., President and CEO of Repligen. "Both awards recognize the value of Repligen's chemical discovery technologies for therapeutic and bioprocessing applications." Repligen Corporation develops new drugs for autism, organ transplant and cancer. Repligen also manufactures and markets a set of patented products based on Protein A which are used by the pharmaceutical industry to produce therapeutic antibodies. Its corporate headquarters are located at 117 Fourth Avenue, Needham, MA 02494. Additional information may be requested from www.repligen.com. This press release contains forward-looking statements based on current management expectations. There are certain key factors which could cause future results to differ materially from those anticipated by management. Such factors include, but are not limited to: uncertainty in the realization of future revenues, the uncertain timeline for clinical activity, results of pending or future clinical trials, the Company's ability to continue to establish collaborative arrangements with third parties; the Company's ability to maintain financial stability; the technical risks associated with development and manufacture of clinical products; the fact that there can be no assurances that patents relating to the Company's potential products will afford adequate protection to the Company, the risks of technological change and competition, and the competitive environment of the biotechnology and pharmaceutical industries. These factors are more fully discussed in the Company's periodic filings with the Securities and Exchange Commission. SOURCE Repligen Corporation /CONTACT: Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation, 781-449-9560, ext. 2000/ /Web site: repligen.com